← Back to patent-cliff list
Isomyosamine
Tier C — Watch / tradeIsomyosamine
Mymd Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TNFα, IL17A, IL6
Indications (approved)：脆弱, 肌肉减少症, Anxiety, COVID-19, Inflammatory disease, Depression, 健康老龄化, Rheumatoid arthritis
Regional status
US
Phase II
2022-02-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Isomyosamine?
Approved indications include: 脆弱, 肌肉减少症, Anxiety, COVID-19, Inflammatory disease, Depression, 健康老龄化, Rheumatoid arthritis.
When does the Isomyosamine patent expire?
No public expiry year is available for Isomyosamine yet; this page updates once verified.
How do I get a quote for Isomyosamine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05